Serum heat inactivation diminishes ApoE-mediated uptake of D-Lin-MC3-DMA lipid nanoparticles

• Demian van Straten,
• Luuk van de Schepop,
• Rowan Frunt,
• Pieter Vader and
• Raymond M. Schiffelers

Beilstein J. Nanotechnol. 2025, 16, 740–748, doi:10.3762/bjnano.16.57

• surface of nanoparticles after administration has garnered substantial attention due to the significant effects it has on their performance. Lipid nanoparticles (LNPs) depend on protein corona formation to mediate their targeting. Such protein–nanoparticle interactions are often initially studied using in

• a crucial part during pre-clinical nanoparticle development. The influence of the protein corona is particularly evident for the efficacy of lipid nanoparticles used for RNA delivery. Lipid nanoparticles (LNPs) protect the encapsulated RNA from premature clearance and simultaneously facilitate the

Aprepitant-loaded solid lipid nanoparticles: a novel approach to enhance oral bioavailability

• Mazhar Hussain,
• Muhammad Farooq,
• Muhammad Asad Saeed,
• Muhammad Ijaz,
• Sherjeel Adnan,
• Zeeshan Masood,
• Muhammad Waqas,
• Wafa Ishaq and
• Nabeela Ameer

Beilstein J. Nanotechnol. 2025, 16, 652–663, doi:10.3762/bjnano.16.50

• , Robert Stevenson Road, Edinburgh, EH9 3FB, United Kingdom 10.3762/bjnano.16.50 Abstract Objectives of the present study are the development of aprepitant (APT)-loaded solid lipid nanoparticles (SLNs) using the polymers poloxamer 407 and β-cyclodextrin for enhanced solubility and their pharmacokinetic

• . Therefore, the optimal SLN formulation APT-CD-NP4 is a promising tool for oral administration with sustained release to improve the bioavailability of the BCS class-IV drug APT. Keywords: aprepitant; β-cyclodextrin; pharmacokinetic study; poloxamer; solid lipid nanoparticles; Introduction Cancer is a

• class-IV drug [10]. Low solubility and poor dissolution of BCS class-IV drugs can be improved by using techniques such as incorporating the drug or prodrug into lipid or polymeric formulations, using solid lipid nanoparticles (SLNs), applying surfactants, adjusting the pH value, reducing particle size

Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment

• Ana Cubillo Alvarez,
• Dylan Maguire and
• Ruairí P. Brannigan

Beilstein J. Nanotechnol. 2025, 16, 435–463, doi:10.3762/bjnano.16.34

• antitumour activity in xenograft mouse models. Later experiments investigated the effect resulting from the incorporation of targeting agents into the surface of lipid–polycation vectors. For example, Yuan et al. prepared transferrin-conjugated PEI1200–lipid nanoparticles (LPNs), for the targeted delivery of

• exhibited greater splice correction effectiveness on mRNA and protein levels, measured by the increase in luciferase activity on engineered HeLa cells containing an altered luciferase gene. In later reports, Yang et al. demonstrated that bPEI–lipid nanoparticles functionalised with small cell-penetrating

Recent advances in photothermal nanomaterials for ophthalmic applications

• Jiayuan Zhuang,
• Linhui Jia,
• Chenghao Li,
• Rui Yang,
• Jiapeng Wang,
• Wen-an Wang,
• Heng Zhou and
• Xiangxia Luo

Beilstein J. Nanotechnol. 2025, 16, 195–215, doi:10.3762/bjnano.16.16

• bovine ILM and the unusually thick human ILM. In addition, this photoporation strategy allowed model nanoparticles to break through the ILM barrier for highly successful delivery to the retina and was also able to increase the efficacy of mRNA-loaded lipid nanoparticles in the bovine retina fivefold. In

Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

• high buffering capacities in the acidic pH range of endosomes (pH 5–6). Lipid nanoparticles (LNPs), which include cationic and ionizable materials, exhibit such intracellularly triggered delivery mechanisms and are often used to carry nucleic acids into cells. In this case, the endosomal escape is

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• ; intranasal delivery; liposomes; nanomedicine; nanostructured lipid carriers (NLCs); polymer nanoparticles; RNA delivery; solid lipid nanoparticles (SLNs); Introduction The central nervous system (CNS) consists of the brain and the spinal cord and is considered the body’s processing and control center. While

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• fact that there are over 50 nanotechnology-based medical products approved by regulatory bodies worldwide for various medical purposes, including AmBisome® (liposomal amphotericin B) for fungal infections, Visudyn® (liposomal vertepor) for macular degeneration, and Onpattro® (lipid nanoparticles with

Classification and application of metal-based nanoantioxidants in medicine and healthcare

• Nguyen Nhat Nam,
• Nguyen Khoi Song Tran,
• Tan Tai Nguyen,
• Nguyen Ngoc Trai,
• Nguyen Phuong Thuy,
• Hoang Dang Khoa Do,
• Nhu Hoa Thi Tran and
• Kieu The Loan Trinh

Beilstein J. Nanotechnol. 2024, 15, 396–415, doi:10.3762/bjnano.15.36

• : (1) nanoliposomes, which are a nanoscale bilayer lipid vesicle [132]; (2) nanocapsules, which consist of an inner aqueous core surrounded by a nontoxic polymeric membrane [133]; (3) solid lipid nanoparticles, which consist of a solid lipid core stabilized by a surfactant [134]; and (4) nanocrystals

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• countries’ institutions (Brazil and Argentina), and private pharmaceutical companies. The project started proposing a sublingual formulation of BNZ within liposomes or lipid nanoparticles, assuming the intact formulations could reach the blood, avoid the hepatic first-pass metabolism, and reduce the

• toxicity of BNZ. The project, however, failed in its attempt to incorporate BNZ into liposomes, while lipid nanoparticles could not be formulated into sublingual tablets. The project changed to formulate BNZ/hydroxypropyl-β-cyclodextrin complexes. These complexes were prepared on a scale seven times larger

• nanoparticles orally and intravenously administered has also been tested (Table 3). For example, oral solid lipid nanoparticles loaded with a poorly bioavailable lipophilic cyclic compound derived from dithiocarbazate, effectively reduced parasitemia, diminished inflammation and lesions of the liver and heart

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

• Douglas Dourado,
• Thayse Silva Medeiros,
• Éverton do Nascimento Alencar,
• Edijane Matos Sales and
• Fábio Rocha Formiga

Beilstein J. Nanotechnol. 2024, 15, 37–50, doi:10.3762/bjnano.15.4

• , lipid nanoparticles, nano- and microemulsions, liposomes, or metallic nanoparticles [68]. Costa-Lima and colleagues incorporated bisnaphthalimidopropyldiaaminooctane (BNIPDaoct) into PLGA polymeric nanoparticles and obtained particles with sizes around 150 nm, with encapsulation efficiency around 90

• following the Ambisome® path. Nanostructured lipid carriers Nanostructured lipid carriers (NLCs) are lipid-based formulations with a solid matrix at room temperature that differ from solid lipid nanoparticles when it comes to their matrix organizational level. Nanostructured lipid carriers offer advantages

• such as enhanced stability, low toxicity, increased shelf life, improved drug loading capacity, and biocompatibility over other conventional lipid-based nanocarriers, such as nanoemulsions and solid lipid nanoparticles [91]. Due to their properties, the use of NLCs has been a successful strategy for

Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• lipid nanoparticles (SLN) are solid lipid matrices at room and body temperature [35]. Their advantages are similar to classic nanocarriers, such as protection of labile drugs from biodegradation process, excellent excipient tolerability, and prolonged release. In addition, some disadvantages of the

• liposomes (500 mg/kg) could be more efficient than free PZQ treatment. Similar results have been shown in other works that also used liposome with PZQ in different concentrations [50][51][52][53]. In addition, Xie et al. [54] studied the pharmacokinetics of solid lipid nanoparticles composed of castor oil

• encapsulating PZQ. They observed that the drug took more than one week in vitro to be released. A pharmacokinetic study in vivo also showed that the PZQ concentration in the plasma was sustained for longer times when the nanoformulation was studied in mice. Thus, the results show that solid lipid nanoparticles

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies

• Giuliana Muraca,
• María Esperanza Ruiz,
• Rocío C. Gambaro,
• Sebastián Scioli-Montoto,
• María Laura Sbaraglini,
• Gisel Padula,
• José Sebastián Cisneros,
• Cecilia Yamil Chain,
• Vera A. Álvarez,
• Cristián Huck-Iriart,
• Guillermo R. Castro,
• María Belén Piñero,
• Matias Ildebrando Marchetto,
• Catalina Alba Soto,
• Germán A. Islan and
• Alan Talevi

Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66

• efficiently. Many developments have been made in the past years resulting in lipid formulations such as liposomes, solid lipid nanoparticles (SLNs), and nanoemulsions, which increased the apparent solubility of BNZ and its efficacy against parasites [17]. Remarkably, oil-in-water nanoemulsions improved the

The steep road to nonviral nanomedicines: Frequent challenges and culprits in designing nanoparticles for gene therapy

• Yao Yao,
• Yeongun Ko,
• Grant Grasman,
• Jeffery E. Raymond and
• Joerg Lahann

Beilstein J. Nanotechnol. 2023, 14, 351–361, doi:10.3762/bjnano.14.30

• polymeric (e.g., core–shell micelles), oligomeric (e.g., lipid nanoparticles), or biomacromolecular (e.g., protein nanoparticles) components complicates matters only further by generating a higher-than-normal background through non-specific interactions with the assay media. In addition, a significant bias

Polymer nanoparticles from low-energy nanoemulsions for biomedical applications

• Santiago Grijalvo and
• Carlos Rodriguez-Abreu

Beilstein J. Nanotechnol. 2023, 14, 339–350, doi:10.3762/bjnano.14.29

• escape from endosomes. Notably, lipid nanoparticles enabled the remarkably fast development of mRNA vaccines against COVID-19. Still, there is much to be done to reach the final goal of developing formulations that can deliver drugs at preset rates and periods of time to specific targets [1]. To this end

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• the nanosystems [136][137]. Lipid nanoparticles (LNPs) in clinical trials are mainly composed of ionizable cationic lipids, amphipathic phospholipids, cholesterol, diffusible PEG lipids (for transient protection), and a targeting ligand [138]. After IV administration, lung capillaries receive the

• payload into the cytoplasm and efficacious transfection [142][143][144][145][146][147][148]. Besides the efforts for liver and liver hepatocyte targeting, different research groups are working on the challenge of developing lipid nanoparticles for specific organ targeting after IV administration

• , including lipid nanoparticles for lung targeting or targeting relevant cell types, that is, epithelial cells, endothelial cells, immune cells of the lungs, B cells, and T cells. Data regarding the biodistribution of polymers, polymer lipids, and lipid nanoparticles indicate that the internal and external

Facile preparation of Au- and BODIPY-grafted lipid nanoparticles for synergized photothermal therapy

• Yuran Wang,
• Xudong Li,
• Haijun Chen and
• Yu Gao

Beilstein J. Nanotechnol. 2022, 13, 1432–1444, doi:10.3762/bjnano.13.118

• nanoparticles limit their therapeutic applications. Previously, gold nanoclusters carrying lipid nanoparticles (Au-LNPs) have been reported after simply mixing Au3+ with preformed diethylenetriaminepentaacetic acid lipid nanoparticles to solve this contradiction. Au-LNPs demonstrated enhanced photothermal

• synergistic PTT in the treatment of cancer and other diseases. Keywords: BODIPY; gold nanoparticles; lipid nanoparticles; photothermal therapy; synergism; Introduction Photothermal therapy (PTT) relies on photothermal agents (PTAs) to convert light into heat energy to burn cancer cells. Due to its spatial

• reported for PTT use. In a previous reported work, we synthesized tiny gold nanoclusters by simply mixing Au3+ with preformed lipid nanoparticles (LNPs) containing diethylenetriaminepentaacetic acid (DTPA) [8]. The Au-grafted LNPs (Au-LNPs) showed significantly enhanced photothermal effects in comparison

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• treatments, which was accompanied by a dose-dependent increase in cytochrome C expression and a dose-dependent decrease in CDK1 expression. Solid lipid nanoparticles (SLN). SLN were first developed ca. 1990 (with patents and papers published a few years after) [60] and are the first generation of lipid

• -loaded polymeric (PNP with PLGA) and lipid nanoparticles (SLN with hydrogenated coco-glycerides and poloxamer 188). They reported greater stability at 135 days (>90% retention), lower average particle size (127.10 ± 11.30 nm), and higher EE% (90.49 ± 1.20%) in CUR-SL, as compared to CUR-PNP (338.20

• nanoparticles (50–1000 nm) [61]. They contain crystallized lipid droplets that are solid at room and body temperatures [62][63], with the drug or the molecule of interest loaded into the solid lipid phase [64]. The advantages of SLN include high drug loading capacity, great stability, good biocompatibility, and

Photothermally active nanoparticles as a promising tool for eliminating bacteria and biofilms

• Mykola Borzenkov,
• Piersandro Pallavicini,
• Angelo Taglietti,
• Laura D’Alfonso,
• Maddalena Collini and
• Giuseppe Chirico

Beilstein J. Nanotechnol. 2020, 11, 1134–1146, doi:10.3762/bjnano.11.98

• studied. The state-of-the art in antimicrobial polymeric nanoparticles, with an emphasis on the relationship between their structure and activity, is well presented in a recent review [29]. The antibacterial properties of solid lipid nanoparticles are also a subject of specific research interest as they

Key for crossing the BBB with nanoparticles: the rational design

• Sonia M. Lombardo,
• Marc Schneider,
• Akif E. Türeli and
• Nazende Günday Türeli

Beilstein J. Nanotechnol. 2020, 11, 866–883, doi:10.3762/bjnano.11.72

• nanoparticles (AuNPs); blood–brain barrier (BBB); drug delivery; liposomes; nanomedicine; polymeric nanoparticles; solid lipid nanoparticles; superparamagnetic iron oxide nanoparticles (SPIONs); Introduction Neurological disorders and brain diseases are real burdens for modern societies and healthcare systems

• the survival time of mice when loaded with paclitaxel. Thus, this formulation could be a promising drug delivery system for antitumor therapy. Solid lipid nanoparticles: Solid lipid nanoparticles (SLNs) are particles with a solid lipid core at room and body temperature [27]. SLNs can be prepared with

Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine

• Valentina Francia,
• Daphne Montizaan and
• Anna Salvati

Beilstein J. Nanotechnol. 2020, 11, 338–353, doi:10.3762/bjnano.11.25

• of 100 nm silica nanoparticles incubated with human serum were found to interact with their corresponding receptors, low-density lipoprotein receptor and Fc-gamma receptor I, respectively [17]. Similarly, lipid nanoparticles were efficiently targeted to the hepatocytes upon adsorption of apoE on

The different ways to chitosan/hyaluronic acid nanoparticles: templated vs direct complexation. Influence of particle preparation on morphology, cell uptake and silencing efficiency

• Arianna Gennari,
• Julio M. Rios de la Rosa,
• Erwin Hohn,
• Maria Pelliccia,
• Enrique Lallana,
• Roberto Donno,
• Annalisa Tirella and
• Nicola Tirelli

Beilstein J. Nanotechnol. 2019, 10, 2594–2608, doi:10.3762/bjnano.10.250

• to 0.5 mg/mL in both models (Figure 5A). Despite the fragile nature of macrophages, the low toxicity seen for HA-coated chitosan nanoparticles is in accordance with what reported in RAW 264.7 macrophages for other HA-based nanomaterials, such as HA-coated liposomes [36] and a library of lipid

• nanoparticles with surface-anchored HA [37], or chitosan-based carriers, such as mannosylated chitosan nanoparticles [38] or siRNA-entrapped chitosan nanoparticles (with or without TPP) [39]. The innocuous character of HA-coated chitosan nanoparticles in HCT-116 is also consistent with previous studies on HA

Frontiers in pharmaceutical nanotechnology

• Matthias G. Wacker

Beilstein J. Nanotechnol. 2019, 10, 2538–2540, doi:10.3762/bjnano.10.244

• announced the approval of a first-of-its-kind RNA interference (RNAi)-based drug, Onpattro™, which uses solid lipid nanoparticles to protect the sensitive compound from early degradation. Again, lipid materials rather than synthetic polymers have been used for drug delivery applications. In pharmaceutical

BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products

• Florence Olechowski,
• Rainer H. Müller and
• Sung Min Pyo

Beilstein J. Nanotechnol. 2019, 10, 2152–2162, doi:10.3762/bjnano.10.208

• Abstract SmartLipids are the latest generation of dermal lipid nanoparticles with solid particle matrix. Their characteristic properties resulting from the “chaotic” and disordered particle matrix structure are reviewed. These properties are high loading and firm inclusion of active agents, physical

• stability of the particle matrix lipid modification (primarily α, β′), and related to these three properties the improved chemical stabilization of labile active agents. Exemplarily data for these effects are shown and underlying mechanisms are discussed. Further, general properties of lipid nanoparticles

• inclusion; nanostructured lipid carriers (NLCs); penetration enhancement; skin occlusion; SmartLipids; solid lipid nanoparticles (SLNs); Introduction To meet the increasing expectations and demands of consumers in personal care and cosmetics, as well of patients in medical care, dermal delivery systems are

Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells

• Liang Xu,
• Dekang Xu,
• Ziying Li,
• Yu Gao and
• Haijun Chen

Beilstein J. Nanotechnol. 2019, 10, 1933–1942, doi:10.3762/bjnano.10.189

• , Di phytosomes (DiP) and P2 phytosomes (P2P) were prepared by a thin-film rehydration method (Figure 3A). Blank lipid nanoparticles without drugs (P) were also prepared with the same process. Particle size and zeta potential of the phytosomes were measured by dynamic light scattering (DLS). The

• . The results showed that the addition of Di and P2 decreased the particle size of lipid nanoparticles. Particle sizes of 100 nm diameter or less will be beneficial to the blood circulation and tumor accumulation [33]. Numerous studies have shown that cholesterol is crucial for the structural stability

• the blank lipid nanoparticles was first investigated. As shown in Figure 4, P did not show any antiproliferative effects on A549 and PC9 cells, indicating the safety of the carrier material. DiP and P2P showed efficient antiproliferative activity in a dose- and time-dependent manner. DiP and P2P

Microfluidic manufacturing of different niosomes nanoparticles for curcumin encapsulation: Physical characteristics, encapsulation efficacy, and drug release

• Mohammad A. Obeid,
• Ibrahim Khadra,
• Abdullah Albaloushi,
• Margaret Mullin,
• Hanin Alyamani and
• Valerie A. Ferro

Beilstein J. Nanotechnol. 2019, 10, 1826–1832, doi:10.3762/bjnano.10.177

• unwanted side effects [8][9]. Liposomes, solid lipid nanoparticles, dendrimers, micelles, polymeric nanoparticles, gold nanoparticles, and carbon nanotubes are among the most common types of nanoparticle delivery systems [10]. These efforts have been reported in several studies. For example, Guo et al